The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example
|
|
- Joleen Conley
- 5 years ago
- Views:
Transcription
1 The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example KENNETH R. HANDE Vanderbilt University School of Medicine, Nashville VA Medical Center, Nashville, Tennessee, USA Key Words. Etoposide Administration schedule Cancer pharmacology Bioavailability Pharmacodynamics Pharmacokinetics ABSTRACT Etoposide is a drug whose antineoplastic activity is dependent on the schedule of drug administration. This article reviews the rationale for a prolonged schedule of etoposide administration and the therapeutic results of use of such a schedule in the treatment INTRODUCTION Most drugs with recognized administration schedule dependence are antimetabolites. In the 1960s, cytosine arabinoside was shown to be inactive unless given as a prolonged infusion or on a multiple-day administration schedule [1]. Toxicity from methotrexate is related to the duration of time a plasma concentration adequate to inhibit dihydrofolate reductase is maintained [2]. The toxicity of 5-fluorouracil depends on its administration schedule, with weekly bolus doses producing more myelosuppression and infusions of several days producing greater gastrointestinal toxicity [3]. For other antineoplastic agents, however, the schedule of drug administration has not been felt to be as important in determining cytotoxicity. However, clinical studies performed over the past few years have shown that the schedule of drug administration is important in altering the cytotoxicity of several antineoplastic drugs, including etoposide and Taxol, which are not classical antimetabolites. The effect of the administration schedule on etoposide cytotoxicity is the subject of this review. RATIONALE FOR CHRONIC ETOPOSIDE THERAPY Several preclinical and clinical findings suggest that the duration of exposure of neoplastic cells to etoposide is important in producing maximal antitumor activity. Mammalian DNA topoisomerase II is the target site for etoposide action. This enzyme normally functions within the cell to carry out necessary breakage-reunion reactions of mammalian DNA. It is a constituent of the mitotic chromosome scaffold. One of the primary physiologic of cancer. The pharmacology of etoposide is also reviewed, with particular attention paid to the pharmacokinetics of oral etoposide and etoposide plasma concentrations associated with cytotoxicity. The Oncologist 1996;1: activities of topoisomerase II is the untangling of daughter chromosomes during mitosis. This process requires passage of an intact double-stranded DNA (dsdna) helix through a transiently formed break made in the backbone of a second helix molecule by topoisomerase II [4]. Etoposide inhibits the ability of topoisomerase II to reseal these transiently formed DNA strand breaks [5]. It causes dose-dependent single-strand and dsdna breaks when incubated with cells. When etoposide is removed, DNA breakage is quickly repaired. The interaction of etoposide and DNA leads to cell cycle arrest in G 2 and subsequent triggering of apoptosis (programmed cell death) [6]. Apoptosis, induced by etoposide, is enhanced by the presence of certain oncogene products, growth factors (such as transforming growth factor α) and the p53 gene, while it is inhibited by the bcl-2 protein [7, 8]. Etoposide s target, topoisomerase II, is significantly expressed only in dividing cells during selected mitotic phases of the cell cycle [9]. Chronic scheduling may therefore be advantageous because it maximizes the likelihood of exposing malignant cells to etoposide during sensitive periods of the cell cycle. Cytotoxicity of topoisomerase II-targeting drugs relates not only to the magnitude of formation of drug-induced, enzyme-mediated DNA strand breaks, but also to the intracellular half-life of these lesions [10]. Therefore, antineoplastic agents or protracted scheduling schemes that prolong the presence of DNA strand breaks in the cell would be expected to result in superior efficacy. In vitro, lymphoma cells exposed to less than 1 µg/ml etoposide for 30 h can be completely killed [11]. Finally, high and Correspondence: Kenneth R. Hande, M.D., Vanderbilt University School of Medicine, Medical Oncology, 1956 The Vanderbilt Clinic, Nashville, TN 37232, USA. Telephone: ; Fax: AlphaMed Press /96/$5.00/0 The Oncologist 1996;1:
2 235 Etoposide low etoposide concentrations exhibit differential effects on cell cycle events. Though not clearly understood, the combination of high concentrations and brief duration of exposure to etoposide appears to result in a relatively protective effect by freezing a proportion of cells in phases of the cell cycle during which the drug is nonlethal. In cellular studies with etoposide, Drewinko and Barlogie [12] demonstrated that a 1 h exposure to 10 µg/ml etoposide resulted in 100-fold less cytotoxicity when compared to prolonged exposure to 1 µg/ml concentrations. Although the importance of drug administration schedule on etoposide s antineoplastic activity was suggested in early preclinical and clinical trials, the most informative studies on the importance of schedule dependence have been conducted by investigators from St. Bartholomew s Hospital in London. In two consecutive studies, the effect of changing the administration schedule of 500 mg etoposide on antineoplastic activity and toxicity was determined. In the first study [13], patients with previously untreated small cell lung cancer (SCLC) were randomized to receive 500 mg/m 2 etoposide either as a 24 h i.v. infusion or as five daily 2 h infusions. Though both patient groups received the same total drug dose, differences in response rates were dramatic. In the one-day treatment arm, 10% of patients responded to therapy, compared to an 89% response rate in the five-day treatment arm (Table 1). Pharmacokinetic data from this trial revealed no significant difference in area under the concentration time curve (AUC) measurements between these two treatment arms. However, prolonged maintenance of low serum etoposide concentrations ( 1 µg/ml) was associated with superior efficacy in the five-day treatment arm. High etoposide concentrations (>10 µg/ml) were maintained for considerably longer periods in the less effective one-day arm than in the superior five-day arm (23 versus 11 h, respectively). In a subsequent study in SCLC [14], a five-day schedule was compared to an eight-day schedule for administration of 500 mg etoposide. In this second study, patients were of poorer performance status than in the initial study and toxicity from etoposide was greater than that seen in the initial trial. The five- and eight-day schedules were found to have equivalent antineoplastic activity (Table 1). Hematologic toxicity was greater in the five-day arm. Duration of time with plasma etoposide concentrations >3 µg/ml was associated with the degree of myelosuppression. These two studies suggest that prolonged exposure to low concentrations of etoposide may improve the therapeutic ratio of this drug. CHRONIC, ORAL ETOPOSIDE ADMINISTRATION In an attempt to determine if an administration schedule longer than the standard three- to five-day regimens would improve the therapeutic index of etoposide, a phase I study was conducted at Vanderbilt using oral etoposide administered daily for 21 days [15]. An oral administration regimen was chosen for the practical reason of making long-term administration simple, and a 21-day duration was chosen to be significantly longer than standard regimens. Myelosuppression was found to be the dose-limiting toxicity. The maximal tolerated dose of etoposide on this schedule was 50 mg/m 2 /day. With this regimen, blood counts were checked weekly and etoposide was discontinued when the WBC count fell below 2,000/µl or platelets below 75,000/µl. Etoposide was not restarted until the WBC was >3,000/µl. In patients having a leukocyte nadir <1,000/µl or who needed to stop the drug before 21 days, a 75% dose reduction was used during the subsequent cycle. With this schedule, leukocyte nadirs occurred between days 21 and 28 of therapy and recovered by days 28-36, in most cases. Toxicity was greater in previously treated patients (Table 2). Other than myelosuppression, this treatment regimen was well tolerated. Red cell transfusions were often needed following multiple cycles of therapy. Alopecia was universal. Nausea, vomiting, mucositis or diarrhea were uncommon or very mild. Several phase II studies using either 50 mg or 50 mg/m 2 etoposide once or twice daily for 14 to 21 days have now been Table 1. Schedule dependency of 500 mg etoposide in small cell lung cancer (from [13] and [14]) Study 1 Study 1 Study 2 Study 2 (1 Day) (5 Day) (5 Day) (8 Day) Response rate 10% 89% 81% 87% Median survival (months) Neutrophil nadir 2,600/µl 2,600/µl 800/µl 1,700/µl Plasma concentration >10 µg/ml 23 h 11 h 11 h 4 h Plasma concentration >5 µg/ml 32 h 34 h 32 h 26 h Plasma concentration >1 µg/ml 46 h 94 h 98 h 106 h AUC (µg/ml h)
3 Hande 236 conducted involving patients with both previously treated and untreated lung cancer [16-18], lymphoma [19], previously treated germ cell tumors [20, 21], soft tissue sarcomas [21], ovarian cancer [22, 23], breast cancer [24, 25], melanoma and renal cell carcinoma. Responses have been seen in all tumor types but were uncommon in melanoma, sarcoma and renal cell carcinomas. Responses have been noteworthy in SCLC, germ cell tumors, and non-hodgkin s lymphoma (Table 3). Overall, response rates have been equal to or greater than expected from historical data from similar patient populations given standard doses and schedules of etoposide. In addition, several patients with SCLC, lymphomas and germ cell tumors who responded to the chronic schedule were previously clinically resistant to standard doses and schedules. While daily oral etoposide has significant activity, is easy to administer, has tolerable toxicity and produces responses in patients who have previously received drugs in other schedules, it does not necessarily improve response rates over standard etoposide-containing regimens in every situation. In a recent study by the Cancer and Leukemia Group B, patients with SCLC were randomized to receive cisplatin with three days of etoposide i.v., or low-dose etoposide p.o. for 21 days [26]. Response rates and median survival were equivalent in the two arms. When used in combination chemotherapy as initial therapy, the administration schedule did not produce significant changes in the therapeutic index of etoposide. ETOPOSIDE PHARMACOLOGY Kinetic parameters associated with i.v. etoposide administration, as determined at Vanderbilt, are shown in Table 4 [27]. The AUC and peak plasma concentrations following i.v. etoposide administration are linearly related to dose [28]. Thirty percent to 40% of an administered dose of drug is excreted unchanged in the urine [28, 29]. Direct biliary excretion of etoposide appears to be a minor route of drug elimination [30]. Obstructive jaundice does not alter the clearance rate of etoposide. Etoposide is highly bound to plasma proteins with an average free plasma fraction of 6%. The etoposide plasma-binding ratio (the amount of bound drug/the amount of free drug) is directly related to the serum albumin level [31]. Many patients with cancer have reduced serum albumin levels and, therefore, a higher free etoposide fraction (13%) than normal volunteers (4%). Since the free drug is biologically active, conditions which decrease protein binding may increase the pharmacologic effect of a given dose. The use of oral etoposide provides a convenient, tolerable treatment regimen which avoids the need for hospitalization. Depending on the cost of intravenous fluids, supplies used for chemotherapy administration and drug Table 2. Hematologic toxicity of 50 mg/m 2 /day 21 days oral etoposide (from [15, 17 19]) Toxicity Previously treated patients Untreated patients Leukocytes < /l 20% 6% Platelets < /l 20% 0% Erythrocyte transfusion 45% 36% Table 3. Activity of chronic, low-dose oral etoposide Disease Response rate Reference Small cell lung cancer 45% (n = 22) [16] 60% (n = 27) [17] Non-small cell lung cancer 20% (n = 25) [18] Lymphoma 60% (n = 25) [19] Germinal tumors 19% (n = 17) [20] 60% (n = 5) [21] Ovarian cancer 18% (n = 17) [21] 6% (n = 18) [22] 26% (n = 28) [23] Breast cancer 35% (n = 43) [24] 20% (n = 36) [25] Table 4. Etoposide pharmacokinetic parameters (from [27]) Volume of distribution 13.8 ± 7.4 l/min Clearance (plasma) 26.5 ± 9.6 ml/min/m 2 Clearance (renal) 9.3 ± 3.9 ml/min/m 2 Half-life 6.4 ± 2.4 h costs, oral etoposide therapy may be more economical than the use of an intravenous regimen [32]. There are, however, drawbacks to oral etoposide therapy. One disadvantage of oral etoposide is the wide variability from patient to patient in oral etoposide absorption. Table 5 summarizes a series of studies from Vanderbilt and compares the variability in apparent drug clearance as a function of the route of drug administration. Between-patient variability is significantly greater than withinpatient variability. However, administration of drug by the oral route increases variability both within and between patients. As a drug s clearance is equal to the dose of drug given divided by the AUC (Cl = Dose/AUC), the significant interpatient and intrapatient variability in oral etoposide absorption makes it difficult to predict the AUC for any individual oral dose of drug. Careful monitoring of blood counts is thus critical in each patient to assume adequate, but not excessive, drug exposure.
4 237 Etoposide Table 5. Variation in etoposide clearance with different routes of administration Group Administration Coefficient of variation Within same patient i.v. 10.7% (n = 12) Within same patient p.o. 15.7% (n = 11) Between patients i.v. 29.8% (n = 48) Between patients p.o. 38.6% (n = 16) The bioavailability of oral etoposide ranges from 40%-75% with, as mentioned, significant within- and between-patient variability. The absorption of etoposide varies with dose. Table 6 compares kinetic parameters seen following a 100 mg and a 400 mg oral dose of etoposide with those seen following i.v. administration. Oral absorption is linear to doses up to 250 mg. Bioavailability decreases with doses greater than 300 mg. Once absorbed, there is no pharmacologic difference between oral and intravenous etoposide with respect to mechanism of action, half-life or mode of drug elimination. LOW-DOSE INFUSIONAL ETOPOSIDE As previously noted, oral etoposide administration, while convenient, is compromised by variable drug absorption. In addition, administration of 100 mg oral drug produces peak plasma concentrations of 2-4 µg/ml. Since myelosuppression may be dependent on peak etoposide serum levels, while antitumor effect may be related to duration of exposure to a relatively low serum level, the chronic scheduling of etoposide using a long-term low-dose continuous infusion has been investigated as a means of avoiding high peak serum etoposide levels. In a phase I/II clinical trial, etoposide was administered as a continuous infusion by portable infusion pump; the drug was mixed in normal saline at a maximum concentration of 0.4 mg/ml. Twentyfive mg/m 2 /day was selected as the initial dose level. Initially, a 21-day infusion was planned, followed by a oneweek rest. It soon became evident that infusions of more than 21 consecutive days were possible in most patients, and subsequent patients were treated continuously as long as their WBC remained >2,000/mm 2, platelets >75,000/mm 2 and tumor progression was not evident. Patients receiving infusions of 25 mg/m 2 /d who developed myelotoxicity necessitating an interruption of therapy were restarted at a 75% dose reduction. Forty patients were treated in this phase I study [34]. Continuous etoposide infusions could be given for prolonged periods. The duration of etoposide therapy ranged from 2 to 80 weeks (median 17 weeks). The total etoposide dose administered ranged from 375-8,838 mg/m 2 (median 1,620 mg/m 2 ). Myelosuppression was the major toxicity produced by infusional etoposide. Moderate leukopenia (WBC 2,000-3,000/µl) was seen in most patients but precipitous drops in counts from week to week were not seen. A leukocyte count of less than 1,000/µl was experienced in five patients accounting for only 5 of 353 total weeks on therapy. Following discontinuation of therapy, the WBC recovered quickly (two to six days). Two patients developed thrombocytopenia. Anemia requiring a transfusion was observed in 21 patients. Alopecia was universal. Other side effects (anorexia, nausea, fatigue) were mild. Objective responses were seen in 5 of 10 patients with previously treated non-hodgkin s lymphoma and two of three patents with previously untreated SCLC [35]. The mean plasma etoposide concentration in patients receiving 25 mg/m 2 /day was 0.78 ± 0.4 µg/ml (range µg/ml). This study suggests that plasma etoposide concentration of roughly 1 µg/ml can be maintained with minimal myelosuppression and that these concentrations are sufficient for antineoplastic activity, at least against SCLC and lymphoma. Other investigators have also administered infusional etoposide and have attempted to correlate steady-state plasma etoposide concentrations with tumor response. In SCLC, Sarkar et al. [36] found no responses in six patients who maintained etoposide plasma concentrations of <0.75 µg/ml, while 6 of 10 patients with plasma etoposide concentrations of µg/ml responded to infusional etoposide. In non-sclc, responses were seen in 1 of 10 patients with plasma etoposide concentrations less than 1.0 µg/ml, while 7 Table 6. Etoposide kinetics (from [30, 33]) Intravenous 100 mg 400 mg dose oral dose oral dose Peak plasma concentration 3.0 ± 1.8 µg/ml 8.6 ± 2.5 µg/ml Time to peak 2.8 ± 1.8 h 2.9 ± 1.7 h Half-life 6.4 ± 1.8 h 6.6 ± 1.6 h 6.6 ± 1.6 h Clearance 2.7 ± 1.0 l/h 3.8 ± 1.5 l/h 5.1 ± 1.6 l/h Bioavailability 76 ± 22% 48 ± 18%
5 Hande 238 of 17 patients with plasma concentrations of µg/ml responded [37]. These data suggest that etoposide concentrations of µg/ml are required for cytotoxicity but that the specific threshold may vary depending upon tumor type. SUMMARY Preclinical and clinical studies have demonstrated the importance of a more prolonged administration schedule for maximizing the therapeutic index of etoposide. While an optimal treatment regimen remains unknown, a 21-day low-dose oral etoposide regimen has demonstrated significant antitumor activity against a variety of neoplasms. This regimen is convenient to administer and well tolerated when myelosuppression is carefully monitored. It can produce responses in patients who have previously been treated with other etoposide administration regimens. Disadvantages of oral etoposide include the significant variability in drug clearance and the potential for development of a treatmentrelated leukemia [38-40], although this has not been seen with this treatment regimen to date. Plasma etoposide concentrations of µg/ml appear to be associated with cytotoxicity. Higher plasma concentrations may lead to additional myelosuppression. From Advances in Cancer Treatment: The Chabner Symposium. STEM CELLS 1996;14: REFERENCES 1 Frei E, Bickers JN, Hewlett JS et al. Dose schedule and antitumor studies of arabinosyl cytosine. Cancer Res 1969;29: Pinedo HM, Zaharko DS, Bull JM et al. The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion. Cancer Res 1977;37: Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia: JB Lippincott, 1990: Osheroff N, Zechiedrich EL, Gale KC. Catalytic function of DNA topoisomerase II. Bioessays 1991;13: Liu LF. DNA topoisomerase poisons as antitumor drugs. Ann Rev Biochem 1989;58: Walker PR, Smith C, Youdale T et al. Topoisomerase II-reactive chemotherapeutic drugs induce apoptosis in thymocytes. Cancer Res 1991;51: Lowe SW, Ruley BE, Jacks T et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer drugs. Cell 1993;74: Kamesaki S, Kamesaki H, Jorgensen TJ et al. Bcl-2 protein inhibits etoposide-induced apoptosis through its effect on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res 1993;53: Heck MMS, Hittelman AN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci USA 1988;85: Fox ME, Smith PJ. Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mamsa and mitoxantrone. Cancer Res 1990;50: Wolff SN, Grosh WW, Prater K et al. In vitro pharmacodynamic evaluation of VP and implications for chemotherapy. Cancer Chemother Pharmacol 1987;19: Drewinko B, Barlogie B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP Cancer Treat Rep 1976;60: Slevin ML, Clark PI, Joel SP et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 1989;7: Clark PI, Slevin NE, Joel SP et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 1994;12: Hainsworth JD, Johnson DH, Frazier SR et al. Chronic daily administration of oral etoposide a phase I trial. J Clin Oncol 1989;7: Johnson DH, Greco FA, Strupp D et al. Prolonged administration of oral etoposide in patients with relapsed or refractory small cell lung cancer: a phase I trial. J Clin Oncol 1990;8: Sessa C, Zucchetti K, Torri V et al. Chronic oral etoposide in small cell lung cancer: clinical and pharmacokinetic results. Ann Oncol 1993;4: Waits TK, Johnson DH, Hainsworth JD et al. Prolonged administration of oral etoposide in non-small cell lung cancer: a phase II trial. J Clin Oncol 1992;10: Hainsworth JD, Johnson DK, Frazier SR et al. Chronic daily administration of oral etoposide in refractory lymphoma. Eur J Cancer 1990;26: Miller JC, Einhorn LH. Phase II study of daily oral etoposide in refractory germ cell tumors. Semin Oncol 1990;17: Greco FA. Chronic etoposide administration: overview of clinical experience. Cancer Treat Rev 1993;19(suppl): Markman M, Hakes T, Reichman B et al. Phase II trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer. J Cancer Res Clin Oncol 1992;119: Hoskins PJ, Swenerton KD. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 1994;12: Martin M, Lluch A, Casadro A et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994;12:
6 239 Etoposide 25 Calvert AH, Lind MJ, Millward MM et al. Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. Cancer Treat Rev 1993;19(suppl): Miller AA, Herndon J, Hollis D et al. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. J Clin Oncol 1995;13: Hande KR. Etoposide pharmacology. Semin Oncol 1992;19(suppl): Hande KR, Wedlund PJ, Noone RM et al. Pharmacokinetics of high-dose etoposide (VP ) administered to cancer patients. Cancer Res 1984;44: D Incalci M, Rossi C, Zucchetti M et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986;46: Hande KR, Wolff SN, Greco FA et al. Etoposide kinetics in patients with obstructive jaundice. J Clin Oncol 1990;8: Stewart CF, Pieper JA, Arburk SG et al. Altered protein binding of etoposide in patients with cancer. Clin Pharmacol Ther 1989;45: Pashko S, Johnson DH. Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer. Pharmacol Econ 1992;1: Hande KR, Krozely MG, Greco FA et al. Bioavailability of low-dose oral etoposide. J Clin Oncol 1993;11: Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose infusional etoposide in patients with advanced malignancies. Cancer 1994;73: Thompson DS, Hainsworth JD, Hande KR et al. Prolonged administration of low-dose infusional etoposide in patients with etoposide sensitive neoplasms: a phase I/II study. J Clin Oncol 1993;11: Sarkar M, Higa G, Robbins A et al. Determination of a therapeutic window and a pharmacokinetic pharmacodynamic model for chronic low-dose etoposide. Proc Am Soc Clin Oncol 1993;13: Kunitoh H, Watanabe K. A phase I/II and pharmacologic study of long-term continuous infusion etoposide combined with cisplatin in patients with lung cancer. J Clin Oncol 1994;12: Pui CH, Ribeiro RC, Hancock ML et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphocytic leukemia. N Engl J Med 1991;325: Nichols CR, Breeded ES, Loehrer PJ et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J Natl Cancer Inst 1993;85: Bajorin DF, Motzer RJ, Rodriguez E et al. Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. J Natl Cancer Inst 1993;85:60-63.
Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity
Clinical Guidelines for Managing Topotecan-Related Hematologic Toxicity DEBORAH ARMSTRONG, SEAMUS O REILLY Johns Hopkins Oncology Center, Baltimore, Maryland, USA Key Words. Topotecan Topoisomerase I inhibitor
More informationAnti-cancer drugs. Introduction : Body : 1) Alkylating Agents
Anti-cancer drugs Introduction : In this journal I will try to explain what is anti-cancer agents, how they work, how can they inhibit the growth of tumor and what is the advantages and disadvantages of
More informationAdverse side effects associated to metronomic chemotherapy
Adverse side effects associated to metronomic chemotherapy Elisabetta Munzone, MD Division of Medical Senology Istituto Europeo di Oncologia Milano, Italy LDM: the optimal biological dose Although there
More informationTopotecan: An Oncologist s View
Topotecan: An Oncologist s View JEAN-FRANÇOIS HÉRON Centre François Baclesse, Centre Régional de Lutte Contre le Cancer, Caen, France Key Words. Topotecan Clinical trials Ovarian neoplasms Small cell lung
More informationInternational Journal of Pharmaceutical and Life Sciences ISSN Volume 2, Issue 5: December 2013
A CHRONOPHARMACOLOGICAL STUDY RELATED TO DOXORUBICIN BASED BONE MARROW SUPPRESSION Dr. Vijayalakshmi Subbiah* 1, Dr. Rajendran K. 2, Dr. Shanthi M. 3, Dr. Parameswari R. 4 1 Professor, Institute of Pharmacology,
More informationPfizer Laboratories (Pty) Ltd P&U Etoposide CSV Range Approved PI: 12 Sep 2005 Page 1 of 5
Approved PI: 12 Sep 2005 Page 1 of 5 SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): P&U ETOPOSIDE CSV 100 mg/5 ml INJECTION (INJECTION CONCENTRATE FOR INTRAVENOUS INFUSION) P&U ETOPOSIDE CSV
More informationCitation Cancer Management and Research, 2(1
NAOSITE: Nagasaki University's Ac Title Author(s) Efficacy and safety of amrubicin hy small cell lung cancer Ogawara, Daiki; Fukuda, Minoru; Nak Citation Cancer Management and Research, 2(1 Issue Date
More informationMethotrexate: is acute oral overdose ever a concern?
Methotrexate: is acute oral overdose ever a concern? Dr Betty Chan Emergency Physician & Clinical Toxicologist Prince of Wales Hospital New South Wales Poisons Information Centre Case Study 1 53F(80kg)
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationPharmacology Updates in Breast Cancer Chris Vaklavas, M.D.
Pharmacology Updates in Breast Cancer Chris Vaklavas, M.D. Assistant Professor Department of Medicine, Division of Hematology/Oncology University of Alabama at Birmingham NP2540M 1802 6th Avenue South
More informationLipoplatin monotherapy for oncologists
Lipoplatin monotherapy for oncologists Dr. George Stathopoulos demonstrated that Lipoplatin monotherapy against adenocarcinomas of the lung can have very high efficacy (38% partial response, 43% stable
More informationVIP (Etoposide, Ifosfamide and Cisplatin)
VIP (Etoposide, Ifosfamide and Cisplatin) Indication First line treatment for metastatic seminoma, non seminoma or combined tumours where bleomycin is contra-indicated. Usually used for patients with intermediate
More informationBasic Concepts of TDM
TDM Lecture 1 5 th stage What is TDM? Basic Concepts of TDM Therapeutic drug monitoring (TDM) is a branch of clinical pharmacology that specializes in the measurement of medication concentrations in blood.
More informationSequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide
Sequential Dose-Dense Adjuvant Therapy With Doxorubicin, Paclitaxel, and Cyclophosphamide Review Article [1] April 01, 1997 By Clifford A. Hudis, MD [2] The recognition of paclitaxel's (Taxol's) activity
More informationWARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,
Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound
More informationSupplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation
Supplementary Table 1: Summary of 33 Patients Treated with Abemaciclib in Dose Escalation Cohort Dose and Frequency Age and Sex Tumor Type Number of Cycles Best Overall Response 4M Colorectal cancer -
More informationVision of the Future: Capecitabine
Vision of the Future: Capecitabine CHRIS TWELVES Cancer Research Campaign Department of Medical Oncology, University of Glasgow, and Beatson Oncology Centre, Glasgow, United Kingdom Key Words. Capecitabine
More information2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation) 3. Antimetabolites (anti-folates, pyrimidine and purine analogues)
CANCER DRUG CLASSES The classes of drugs currently used in the cancer clinic are 1. DNA Binding Agents (intercalating and alkylating agents) 2. Mitotic Spindle Inhibitors (modulators of tubulin polymerisation)
More informationBleomycin, Etoposide and CISplatin (BEP) Therapy
Bleomycin, Etoposide and CISplatin (BEP) Therapy INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Adjuvant treatment of high risk (vascular invasion C62 00300a carcinoma) stage 1 nonseminoma germ cell
More informationBelotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer
J Lung Cancer 2010;9(1):15-19 Belotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive-Disease Small Cell Lung Cancer Purpose: Belotecan (Camtobell R ; Chong Keun Dang Co., Seoul,
More informationVinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trial
Original article Annals of Oncology 14: 699 703, 2003 DOI: 10.1093/annonc/mdg199 Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM
More informationthrough the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.
Hello and welcome to this lecture. My name is Hillary Prescott. I am a Clinical Pharmacy Specialist at The University of Texas MD Anderson Cancer Center. My colleague, Jeff Bryan and I have prepared this
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationUpdate on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Thomas J. Herzog. doi: /theoncologist.
Update on the Role of Topotecan in the Treatment of Recurrent Ovarian Cancer Thomas J. Herzog The Oncologist 2002, 7:3-10. doi: 10.1634/theoncologist.7-suppl_5-3 The online version of this article, along
More informationNCCP Chemotherapy Regimen. Olaparib Monotherapy
Olaparib INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Maintenance treatment of adult patients with platinum -sensitive relapsed BRCAmutated (germline and/or somatic) - high
More informationFDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
October 12, 2012 FDA Approves ABRAXANE for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationClinical Impact of primary prophylaxis for FN in breast cancer patients. Prof. Young Jin Suh The Catholic University of Korea
Clinical Impact of primary prophylaxis for FN in breast cancer patients Prof. Young Jin Suh The Catholic University of Korea Objectives Describe the prevalence of febrile neutropenia in patients with breast
More informationX M/ (R) Dose adjusted (DA)-EPOCH-R
X M/ (R) adjusted (DA)-EPOCH-R Indication High-risk CD20+ diffuse large B cell lymphoma especially C-MYC and BCL-2 activated (i.e. double hit lymphoma) and mediastinal sclerosing (thymic) large B cell
More informationKey Words. Chemotherapy Topotecan Weekly administration
The Oncologist Weekly Topotecan: An Alternative to Topotecan s Standard Daily 5 Schedule? ERIC K. ROWINSKY Institute for Drug Development, The Cancer Therapy and Research Center, The University of Texas
More informationPHA5128 Dose Optimization II Case Study I Spring 2013
Silsamicin is an investigational compound being evaluated for its antimicrobial effect. The route of administration for this drug is via intravenous bolus. Approximately 99.9% of this drug is eliminated
More informationManufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Brand Name: Mylotarg Generic Name: gentuzumab ozogamicin Manufacturer: Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. Drug Class: CD33-directed antibody-drug conjugate Uses: Labeled Uses: Newly-diagnosed
More informationOxaliplatin and Gemcitabine
Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen
More informationCHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling
CHK1 Inhibitor Prexasertib, LY2606368 MsOH H 2 O Derived from Garrett MD and Collins I 1 ; Thompson R and Eastman A. 2 Drug Discovery Platform: Cancer Cell Signaling A Phase 2 Study of LY2606368 in Patients
More informationComparative Study of Toxicity of Weekly versus Three -Weekly Regimen of Paclitaxel in Locally Advanced Breast Cancer
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 79-85, p-issn: 79-86.Volume 5, Issue Ver. IX (December. 6), PP 9-98 www.iosrjournals.org Comparative Study of Toxicity of Weekly versus Three
More informationANNEX I SUMMARY OF PRODUCT CHARACTERISTICS. Medicinal Product no longer authorised
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Topotecan Eagle 3 mg/1 ml concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate
More informationFor the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA
For the use of only Oncologist or a Cancer Hospital or a laboratory Doxorubicin Hydrochloride Liposome Injection 2 mg/ml KEMODOXA COMPOSITION Each ml contains: Doxorubicin Hydrochloride IP...2 mg Water
More informationOWa 22 80) :IEZ
Clinical Study Report: 20025409 Part 2 Date: 22 September 2008 OWa 22 80) 06 --- :IEZ Page 1 SYNOPSIS Name of the Sponsor: Name of Finished Product: Name of Active Ingredient: Immunex Corporation Panitumumab
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationPlatinum-based doublet chemotherapy is the standard firstline
ORIGINAL ARTICLE A Phase II Trial of Carboplatin and Weekly Topotecan in the First-Line Treatment of Patients with Extensive Stage Small Cell Lung Cancer David R. Spigel, MD,* John D. Hainsworth, MD,*
More informationCancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018
Cancer Chemotherapy Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018 االدوية Polyfunctional Alkylating Agents االستخالبية متعددة الوظائف Not cell cycle-specific.
More informationLecture 1: Carcinogenesis
Lecture 1: Carcinogenesis Anti-cancer (oncology agents): These are perhaps the most dangerous of drugs, other than the narcotic analgesics. This is due to their toxicities. Killing or inhibiting cancer
More informationTemozolomide Capsules I.P. Composition TEMOLOZ Each Capsule contains: Temozolomide I.P. 250 mg. TEMOLOZ-100. Each Capsule contains
Temozolomide Capsules I.P. Composition TEMOLOZ -250 Each Capsule contains: Temozolomide I.P. 250 mg. TEMOLOZ-100 Each Capsule contains Temozolomide I.P. 100 mg. TEMOLOZ-20 Each Capsule contains Temozolomide
More informationHDAC Inhibitors and PARP inhibitors. Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine
HDAC Inhibitors and PARP inhibitors Suresh Ramalingam, MD Associate Professor Chief of Thoracic Oncology Emory University School of Medicine Histone Acetylation HAT Ac Ac Ac Ac HDAC Ac Ac Ac Ac mrna DACs
More informationLung cancer is the leading cause of cancer death in the
ORIGINAL ARTICLE A Phase II Randomized Study of Paclitaxel Plus Carboplatin or Cisplatin against Chemo-Naive Inoperable Non-small Cell Lung Cancer in the Elderly Yuh-Min Chen, MD, PhD,* Reury-Perng Perng,
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationCarboplatin Injection BP KEMOCARB
WARNING: For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Carboplatin Injection BP KEMOCARB Carboplatin Injection should be administered under the supervision of a qualified
More informationDrug Comparison: Lartruvo TM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of
Drug Comparison: Lartruvo TM (Olaratumab) for Soft Tissue Sarcoma By: Majd Abedrabbo, PharmD Candidate 2018 Fairleigh Dickinson University School of Pharmacy May 3, 2017 Introduction Soft Tissue Sarcoma
More informationSmall cell lung cancer (SCLC) comprises approximately
Original Article Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients Gun Min Kim, MD,* Young Sam Kim, MD, PhD, Young Ae Kang, MD, PhD, Jae-Heon Jeong, MD, Sun
More informationCombination of three cytotoxic agents in small-cell lung cancer
Cancer Chemother Pharmacol (2013) 71:413 418 DOI 10.1007/s00280-012-2022-8 ORIGINAL ARTICLE Combination of three cytotoxic agents in small-cell lung cancer G. P. Stathopoulos D. Trafalis J. Dimitroulis
More informationNCCP Chemotherapy Regimen. CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell Tumour Regimen
CARBOplatin (AUC7) and Etoposide- Autologous Conditioning Germ Cell INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Treatment of metastatic relapsed/refractory germ cell tumours C62 00453a *Reimbursement
More informationPrinciples of chemotherapy
Principles of chemotherapy Chemotherapy first coined by Paul Ehrlich Aim to selectively destroy cancer cells whilst relatively sparing tumours cells Growth characteristics of cancer cells allows for selective
More informationDRUG NAME: Palbociclib
DRUG NAME: Palbociclib SYNONYM(S): PD 0332991; PD 991; PF 332991 1 COMMON TRADE NAME(S): IBRANCE CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise
More informationDRUG NAME: Palbociclib
DRUG NAME: Palbociclib SYNONYM(S): PD 0332991; PD 991; PF 332991 1 COMMON TRADE NAME(S): IBRANCE CLASSIFICATION: molecular targeted therapy Special pediatric considerations are noted when applicable, otherwise
More informationScottish Medicines Consortium
P Oral) Scottish Medicines Consortium vinorelbine 20 and 30mg capsules (NavelbineP Pierre Fabre Ltd No. (179/05) 06 May 2005 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationSingle-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer
Single-Agent Paclitaxel in the Treatment of Advanced Non-Small Cell Lung Cancer MARK A. SOCINSKI The Multidisciplinary Thoracic Oncology Program, University of North Carolina, Chapel Hill, North Carolina,
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationDATA SHEET. Polycythaemia rubra vera: ALKERAN is effective in the treatment of a proportion of patients suffering from polycythaemia vera.
DATA SHEET 1. PRODUCT NAME (strength pharmaceutical form) ALKERAN TM (Melphalan Tablets 2mg) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 2mg melphalan 3. PHARMACEUTICAL FORM Film-coated
More information(212) (347)
EMBARGOED FOR MONDAY, JUNE 21, 2010: 3:00 P.M. EST For immediate release: June 21, 2010 Media Contact: Curtis Allen (212) 733-2096 (347) 443-5252 Investors Contact: Suzanne Harnett (212) 733-8009 Pfizer
More informationIrinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination
Clinical Report Chemotherapy 2002;48:94 99 Irinotecan (CPT-11) in Patients with Advanced Colon Carcinoma Relapsing after 5-Fluorouracil-Leucovorin Combination N.B. Tsavaris a A. Polyzos b K. Gennatas c
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationFoo Koon Mian Pharmacy Resident National University of Singapore Hematology / Oncology Pharmacy Residency Program. 4th APOPC November 2012
Foo Koon Mian Pharmacy Resident National University of Singapore Hematology / Oncology Pharmacy Residency Program 4th APOPC 2012 1-3 November 2012 1 Outline Use of BSA in chemotherapy dosing Chemotherapy
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationJohns Hopkins Medical Institutions, Baltimore, Maryland, USA
The Oncologist Topotecan Dosing Guidelines in Ovarian Cancer: Reduction and Management of Hematologic Toxicity DEBORAH K. ARMSTRONG Johns Hopkins Medical Institutions, Baltimore, Maryland, USA Key Words.
More informationBC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab
BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.
More informationCisplatin and Pemetrexed (NSCLC, mesothelioma)
Cisplatin and Pemetrexed (NSCLC, mesothelioma) Indication First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) if the histology of the tumour has been confirmed as
More informationESMO DOUBLE-HIT LYMPHOMAS
ESMO DOUBLE-HIT LYMPHOMAS Professor Dr. med. Georg Lenz Director Department of Hematology and Oncology Universitätsklinikum Münster, Germany OVERVIEW Definition of double-hit lymphomas Introduction in
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationLeucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg
Leucovorin Calcium Tablets USP, 5 mg, 10 mg, 15 mg, and 25 mg Rx only DESCRIPTION Leucovorin Calcium Tablets USP contain either 5 mg, 10 mg, 15 mg or 25 mg leucovorin as the calcium salt of N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]
More informationOncologist. The. Cancer Treatment Reports: Early Drug Trials
The Oncologist Cancer Treatment Reports: Early Drug Trials A Phase I Study of Weekly Topotecan in Combination with Pemetrexed in Patients with Advanced Malignancies HOWARD A. BURRIS III, a,b JEFFREY R.
More informationVYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA
VYXEOS : CHEMOTHERAPY LIPOSOME INJECTION FOR ACUTE MYELOID LEUKEMIA Sarah Mae Rogado PharmD Candidate 2017 Preceptors: Rozena Varghese, PharmD, CMPP; Rachel Brown, PharmD MedVal Scientific Information
More informationFor the use only of a Registered Medical Practitioner or a Hospital or a Laboratory
For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory Leucovorin Calcium Injection Zovorin TM Composition: Leucovorin Calcium Injection IP 50mg/5ml Each ml contains: Leucovorin
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationUpdate: New Treatment Modalities
ASH 2008 Update: New Treatment Modalities ASH 2008: Update on new treatment modalities GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationOncology 101. Marianne Davies, RN, APRN Yale Cancer Center September 2006
Oncology 101 Marianne Davies, RN, APRN Yale Cancer Center September 2006 Fundamentals Biology of Cancer Diagnosis Pathology Principles of therapy Schedules/Delivery Toxicities Staging Evaluation of response
More informationRandomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer
Randomized Phase III Trials of Intravenous vs. Intraperitoneal Therapy in Optimal Ovarian Cancer Deborah K. Armstrong, M.D. Associate Professor of Oncology, Gynecology and Obstetrics Development of Intraperitoneal
More informationIrinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer
Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal
More informationCisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE:
Cisplatin + Etoposide + Thoracic Radiotherapy (TRT) INDICATIONS FOR USE: Protocol INDICATION ICD10 Code Small cell lung cancer (SCLC) limited disease C34 00279a ELIGIBILTY: Indications as above ECOG 0-2
More informationOncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date
MP 8.01.03 Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with
More informationGemcitabine (1000mg/m 2 ) Monotherapy - 28 day
Gemcitabine (1000mg/m 2 ) Monotherapy - 28 day INDICATIONS FOR USE: Regimen INDICATION ICD10 Code Adjuvant chemotherapy for pancreatic adenocarcinoma C25 00284a Treatment of elderly patients or patients
More informationAntineoplastic Drugs. Antineoplastic Drugs. Herbal Alert. Pharmacology Chapter 51. Green tea
Antineoplastic Drugs Pharmacology Chapter 51 Carolyn Wright, RN, BSN Ford, S. & Roach, S. (2010). Roach's introductory clinical pharmacology (9 th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationAnthracyclines and Anthracenediones as a Antitumor Agents. Nam Deuk Kim, Ph.D. Pusan National University
Anthracyclines and Anthracenediones as a Antitumor Agents Nam Deuk Kim, Ph.D. Pusan National University 1 Introduction Anthracyclines and anthracenediones are anthracene derivatives. The first anthracycline
More informationEdith A. Perez, Ahmad Awada, Joyce O Shaughnessy, Hope Rugo, Chris Twelves, Seock-Ah Im, Carol Zhao, Ute Hoch, Alison L. Hannah, Javier Cortes
BEACON: A Phase 3 Open-label, Randomized, Multicenter Study of Etirinotecan Pegol (EP) versus Treatment of Physician s Choice (TPC) in Patients With Locally Recurrent or Metastatic Breast Cancer Previously
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationNontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment
Nontraditional PharmD Program PRDO 7700 Pharmacokinetics Review Self-Assessment Please consider the following questions. If you do not feel confident about the material being covered, then it is recommended
More informationPACLitaxel Monotherapy 80mg/m 2 7 days
INDICATIONS FOR USE: PACLitaxel Monotherapy 80mg/m 2 7 days INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of metastatic breast carcinoma (mbc) in patients C50 00226a Hospital who have either
More informationVol. 26 No. 3 September 2003 Journal of Pain and Symptom Management 849
Vol. 26 No. 3 September 2003 Journal of Pain and Symptom Management 849 Original Article Amifostine, in a Reduced Dose, Protects Against Severe Diarrhea Associated with Weekly Fluorouracil and Folinic
More informationSUPPLEMENTARY INFORMATION In format provided by Sebti et al. (NOVEMBER 2011)
Supplementary Information S4 Clinical trials with farnesyltransferase inhibitors Drug(s) Disease Phase Patients Median Age Tipifarnib CR Clinical response PR HI SD PD MD FT or Prenylation Response rate
More informationGEMZAR Eli Lilly. Gemcitabine hydrochloride 1. NAME OF THE MEDICINAL PRODUCT
GEMZAR Eli Lilly Gemcitabine hydrochloride 1. NAME OF THE MEDICINAL PRODUCT Gemzar 200 mg, freeze-dried powder for parenteral use (i.v.) Gemzar 1000 mg, freeze-dried powder for parenteral use (i.v.) 2.
More information